CMPX Compass Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1738021 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-31.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-49.0%
ROA-42.6%
ROIC (approx.)-56.2%
Asset turnover—
Leverage & solvency
Liabilities / assets18.3%
Debt / equity0.00x
Current ratio6.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-12.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | — | $0 |
| R&D expense | $22.04M | $19.58M | $13.39M | $13.67M | $12.83M | $16.41M | $13.05M | $13.04M |
| SG&A expense | $6.76M | $7.40M | $6.91M | $4.32M | $2.99M | $4.65M | $4.91M | $3.54M |
| Operating income | -$28.80M | -$26.98M | -$20.30M | -$17.99M | -$15.82M | -$21.07M | -$17.97M | -$16.57M |
| Pretax income | — | — | — | — | — | — | -$16.63M | — |
| Income tax | — | — | — | — | — | — | $0 | — |
| Net income | -$27.17M | -$25.15M | -$18.32M | -$15.72M | -$14.26M | -$19.88M | -$16.63M | -$15.03M |
| EBITDA | -$28.77M | -$26.96M | -$20.28M | -$17.97M | -$15.80M | -$20.97M | -$17.83M | -$16.43M |
| EPS (basic) | -0.15 | -0.13 | -0.10 | — | -0.08 | -0.14 | -0.12 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Weighted avg. shares (diluted) | — | — | — | — | — | — | 138.20M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $41.47M | $35.45M | $55.17M | $30.64M | $46.21M | $22.86M | $41.05M | $43.48M |
| Short-term investments | $121.59M | $144.43M | $139.52M | $178.26M | $173.68M | $78.09M | $71.59M | $83.24M |
| Current assets | $165.50M | $180.89M | $195.69M | $209.82M | $221.12M | $106.19M | $124.14M | $132.75M |
| PP&E, net | $402,000 | $324,000 | $169,000 | $102,000 | $119,000 | $131,000 | $102,000 | $353,000 |
| Total assets | $174.50M | $190.17M | $205.17M | $219.59M | $231.26M | $116.70M | $131.45M | $140.40M |
| Current liabilities | $24.37M | $16.13M | $10.28M | $13.97M | $12.41M | $13.86M | $14.90M | $8.87M |
| Total liabilities | $31.93M | $24.12M | $18.70M | $22.80M | $21.65M | $23.49M | $21.17M | $15.17M |
| Shareholders' equity | $142.57M | $166.05M | $186.47M | $196.79M | $209.61M | $93.21M | $110.28M | $125.23M |
| Shares outstanding | 180.09M | 180.09M | 180.09M | 178.32M | 177.57M | 138.28M | 138.28M | 137.82M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.32M | -$14.74M | -$17.27M | -$13.25M | -$10.85M | -$11.83M | -$13.21M | -$9.16M |
| Capital expenditure | $106,000 | $176,000 | $82,000 | $0 | $7,000 | $0 | $18,000 | $0 |
| Free cash flow | -$16.42M | -$14.91M | -$17.35M | -$13.25M | -$10.86M | -$11.83M | -$13.23M | -$9.16M |
| Investing cash flow | $22.33M | -$4.98M | $38.43M | -$3.38M | -$95.16M | -$6.36M | $11.59M | $15.37M |
| Financing cash flow | $0 | $0 | $3.37M | $1.06M | $129.36M | $0 | -$815,000 | -$94,000 |
| Depreciation & amortization | $28,000 | $21,000 | $15,000 | $17,000 | $19,000 | $100,000 | $140,000 | $140,000 |
| Stock-based compensation | $4.01M | $4.82M | $5.07M | $1.82M | $1.24M | $2.79M | $2.51M | $2.24M |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.